|
1
|
van Weert S, Bloemena E, van der Waal I,
de Bree R, Rietveld DH, Kuik JD and Leemans CR: Adenoid cystic
carcinoma of the head and neck: A single-center analysis of 105
consecutive cases over a 30-year period. Oral Oncol. 49:824–829.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moskaluk CA: Adenoid cystic carcinoma:
Clinical and molecular features. Head Neck Pathol. 7:17–22. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gondivkar SM, Gadbail AR, Chole R and
Parikh RV: Adenoid cystic carcinoma: A rare clinical entity and
literature review. Oral Oncol. 47:231–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang Y, Liang X, Zheng M, Zhu Z, Zhu G,
Yang J and Chen Y: Expression of c-kit and Slug correlates with
invasion and metastasis of salivary adenoid cystic carcinoma. Oral
Oncol. 46:311–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dodd RL and Slevin NJ: Salivary gland
adenoid cystic carcinoma: A review of chemotherapy and molecular
therapies. Oral Oncol. 42:759–769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Laurie SA, Ho AL, Fury MG, Sherman E and
Pfister DG: Systemic therapy in the management of metastatic or
locally recurrent adenoid cystic carcinoma of the salivary glands:
A systematic review. Lancet Oncol. 12:815–824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu L, Li ZL, Zhao LY, Liu YF, Li GX, Ding
MX, Zhao YQ, Fu Q and Zhao X: Effects of simvastatin on DNA
synthesis in rat cardiac fibroblasts. Nan Fang Yi Ke Da Xue Xue
Bao. 26205–207. (213)2006.(In Chinese). PubMed/NCBI
|
|
8
|
Kavalipati N, Shah J, Ramakrishan A and
Vasnawala H: Pleiotropic effects of statins. Indian J Endocrinol
Metab. 19:554–562. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen W, Garcia JG and Jacobson JR:
Integrin beta4 attenuates SHP-2 and MAPK signaling and reduces
human lung endothelial inflammatory responses. J Cell Biochem.
110:718–724. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu Y, Casey PJ, Kumar AP and Pervaiz S:
Deciphering the signaling networks underlying simvastatin-induced
apoptosis in human cancer cells: Evidence for non-canonical
activation of RhoA and Rac1 GTPases. Cell Death Dis. 4:e5682013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu J, Shao C, Tan ML, Mu D, Ferris RL and
Ha PK: Molecular biology of adenoid cystic carcinoma. Head Neck.
34:1665–1677. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fukuda S and Pelus LM: Survivin, a cancer
target with an emerging role in normal adult tissues. Mol Cancer
Ther. 5:1087–1098. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ko YH, Roh SY, Won HS, Jeon EK, Hong SH,
Lee MA, Kang JH, Hong YS, Kim MS and Jung CK: Prognostic
significance of nuclear survivin expression in resected adenoid
cystic carcinoma of the head and neck. Head Neck Oncol. 2:302010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dresang LR, Guastafierro A, Arora R,
Normolle D, Chang Y and Moore PS: Response of Merkel cell
polyomavirus-positive merkel cell carcinoma xenografts to a
survivin inhibitor. PLoS One. 8:e805432013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Falleni M, Pellegrini C, Marchetti A,
Oprandi B, Buttitta F, Barassi F, Santambrogio L, Coggi G and
Bosari S: Survivin gene expression in early-stage non-small cell
lung cancer. J Pathol. 200:620–626. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schlette EJ, Medeiros LJ, Goy A, Lai R and
Rassidakis GZ: Survivin expression predicts poorer prognosis in
anaplastic large-cell lymphoma. J Clin Oncol. 22:1682–1688. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kogo R, How C, Chaudary N, Bruce J, Shi W,
Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin
axis regulates migration, invasion, and lymph node metastasis in
cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Doğan M, Çağlı S, Yüce İ, Bayram A, Somdaş
MA, Karataş D, Cihan MC, Yüksel F and Güney E: Survivin expression
correlates with nodal metastasis in T1-T2 squamous cell carcinoma
of the tongue. Eur Arch Otorhinolaryngol. 272:689–694. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marioni G, Bertolin A, Giacomelli L,
Marchese-Ragona R, Savastano M, Calgaro N, Marino F, De Filippis C
and Staffieri A: Expression of the apoptosis inhibitor protein
survivin in primary laryngeal carcinoma and cervical lymph node
metastasis. Anticancer Res. 26:3813–3817. 2006.PubMed/NCBI
|
|
21
|
Altieri DC and Marchisio PC: Survivin
apoptosis: An interloper between cell death and cell proliferation
in cancer. Lab Invest. 79:1327–1333. 1999.PubMed/NCBI
|
|
22
|
Jaso J and Malhotra R: Adenoid cystic
carcinoma. Arch Pathol Lab Med. 135:511–515. 2011.PubMed/NCBI
|
|
23
|
Ding LC, Huang XY, Zheng FF, Xie J, She L,
Feng Y, Su BH, Zheng DL and Lu YG: FZD2 inhibits the cell growth
and migration of salivary adenoid cystic carcinomas. Oncol Rep.
35:1006–1012. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Turrell FK, Kerr EM, Gao M, Thorpe H,
Doherty GJ, Cridge J, Shorthouse D, Speed A, Samarajiwa S, Hall BA,
et al: Lung tumors with distinct p53 mutations respond similarly to
p53 targeted therapy but exhibit genotype-specific statin
sensitivity. Genes Dev. Aug 8–2017.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shimoyama S: Statins are logical
candidates for overcoming limitations of targeting therapies on
malignancy: Their potential application to gastrointestinal
cancers. Cancer Chemother Pharmacol. 67:729–739. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matusewicz L, Meissner J, Toporkiewicz M
and Sikorski AF: The effect of statins on cancer cells-review.
Tumour Biol. 36:4889–4904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clendening JW and Penn LZ: Targeting tumor
cell metabolism with statins. Oncogene. 31:4967–4978. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Clendening JW, Pandyra A, Boutros PC, El
Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem
R, Jurisica I and Penn LZ: Dysregulation of the mevalonate pathway
promotes transformation. Proc Natl Acad Sci USA. 107:15051–15056.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nowakowski GS, Maurer MJ, Habermann TM,
Ansell SM, Macon WR, Ristow KM, Allmer C, Slager SL, Witzig TE and
Cerhan JR: Statin use and prognosis in patients with diffuse large
B-cell lymphoma and follicular lymphoma in the rituximab era. J
Clin Oncol. 28:412–417. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mokarram P, Alizadeh J, Razban V, Barazeh
M, Solomon C and Kavousipour S: Interconnection of
estrogen/testosterone metabolism and mevalonate pathway in breast
and prostate cancers. Curr Mol Pharmacol. 10:86–114. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ciaglia E, Grimaldi M, Abate M and Bifulco
M: The isoprenoid derivative N6-benzyladenosine (CM223) exerts
antitumor effect in glioma patient-derived primary cells through
the mevalonate pathway. Br J Pharmacol. 174:2287–2301. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shi J, Zhu J, Zhao H, Zhong C, Xu Z and
Yao F: Mevalonate pathway is a therapeutic target in esophageal
squamous cell carcinoma. Tumour Biol. 34:429–435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang P, Mukthavaram R, Chao Y, Nomura N,
Bharati IS, Fogal V, Pastorino S, Teng D, Cong X, Pingle SC, et al:
In vitro and in vivo anticancer effects of mevalonate pathway
modulation on human cancer cells. Br J Cancer. 111:1562–1571. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Freed-Pastor WA, Mizuno H, Zhao X,
Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li
W, Polotskaia A, et al: Mutant p53 disrupts mammary tissue
architecture via the mevalonate pathway. Cell. 148:244–258. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stamatakis K, Cernuda-Morollón E,
Hernández-Perera O and Pérez-Sala D: Isoprenylation of RhoB is
necessary for its degradation. A novel determinant in the complex
regulation of RhoB expression by the mevalonate pathway. J Biol
Chem. 277:49389–49396. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hwang KE, Na KS, Park DS, Choi KH, Kim BR,
Shim H, Jeong ET and Kim HR: Apoptotic induction by simvastatin in
human lung cancer A549 cells via Akt signaling dependent
down-regulation of survivin. Invest New Drugs. 29:945–952. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boidot R, Végran F and Lizard-Nacol S:
Transcriptional regulation of the survivin gene. Mol Biol Rep.
41:233–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Salman T, Argon A, Kebat T, Vardar E,
Erkan N and Alacacıoğlu A: The prognostic significance of survivin
expression in gallbladder carcinoma. APMIS. 124:633–638. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jaiswal PK, Goel A and Mittal RD:
Survivin: A molecular biomarker in cancer. Indian J Med Res.
141:389–397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin S, Shang Z, Li S, Gao P, Zhang Y, Hou
S, Qin P, Dong Z, Hu T and Chen P: Neddylation inhibitor MLN4924
induces G2 cell cycle arrest, DNA damage and sensitizes esophageal
squamous cell carcinoma cells to cisplatin. Oncol Lett.
15:2583–2589. 2018.PubMed/NCBI
|
|
42
|
Yu C, Cao H, He X, Sun P, Feng Y, Chen L
and Gong H: Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a
critical role in prostate cancer via regulating cell cycle and DNA
replication signaling. Biomed Pharmacother. 96:1109–1118. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lara-Padilla E and Caceres-Cortes JR: On
the nature of the tumor-initiating cell. Curr Stem Cell Res Ther.
7:26–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Utz PJ and Anderson P: Life and death
decisions: Regulation of apoptosis by proteolysis of signaling
molecules. Cell Death Differ. 7:589–602. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu CC, Chang TC, Lin YT, Yu YL, Ko BS,
Sung LY and Liou JY: Paracrine regulation of matrix
metalloproteinases contributes to cancer cell invasion by
hepatocellular carcinoma-secreted 14-3-3σ. Oncotarget.
7:36988–36999. 2016.PubMed/NCBI
|
|
46
|
Yu X, Pan Y, Ma H and Li W: Simvastatin
inhibits proliferation and induces apoptosis in human lung cancer
cells. Oncol Res. 20:351–357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang YF, Ma SR, Wang WM, Huang CF, Zhao
ZL, Liu B, Zhang WF, Zhao YF, Zhang L and Sun ZJ: Inhibition of
survivin reduces HIF-1α, TGF-β1 and TFE3 in salivary adenoid cystic
carcinoma. PLoS One. 9:e1140512014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Farnebo L, Jerhammar F, Ceder R, Grafström
RC, Vainikka L, Thunell L, Grénman R, Johansson AC and Roberg K:
Combining factors on protein and gene level to predict
radioresponse in head and neck cancer cell lines. J Oral Pathol
Med. 40:739–746. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tsuneki M, Kinjo T, Mori T, Yoshida A,
Kuyama K, Ohira A, Miyagi T, Takahashi K, Kawai A, Chuman H, et al:
Survivin: A novel marker and potential therapeutic target for human
angiosarcoma. Cancer Sci. 108:2295–2305. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chang HL, Chen CY, Hsu YF, Kuo WS, Ou G,
Chiu PT, Huang YH and Hsu MJ: Simvastatin induced HCT116 colorectal
cancer cell apoptosis through p38MAPK-p53-survivin signaling
cascade. Biochim Biophys Acta. 1830:4053–4064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hisada T, Ayaori M, Ohrui N, Nakashima H,
Nakaya K, Uto-Kondo H, Yakushiji E, Takiguchi S, Terao Y, Miyamoto
Y, et al: Statin inhibits hypoxia-induced endothelin-1 via
accelerated degradation of HIF-1α in vascular smooth muscle cells.
Cardiovasc Res. 95:251–259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hu D, Liu S, Shi L, Li C, Wu L and Fan Z:
Cleavage of survivin by Granzyme M triggers degradation of the
survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to
free caspase activity leading to cytolysis of target tumor cells. J
Biol Chem. 285:18326–18335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang YF, Ma SR, Wang WM, Huang CF, Zhao
ZL, Liu B, Zhang WF, Zhao YF, Zhang L and Sun ZJ: Inhibition of
survivin reduces HIF-1α, TGF-β1 and TFE3 in salivary adenoid cystic
carcinoma. PLoS One. 9:e1140512014. View Article : Google Scholar : PubMed/NCBI
|
